Carregant...
Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity
Recently reported cardiovascular outcome studies on empagliflozin (EMPA-REG) and liraglutide (LEADER) have spurred interest in this field of diabetology. This commentary compares and contrasts these studies with two equally important outcome trials conducted using blood pressure lowering agents. A c...
Guardat en:
| Publicat a: | Indian J Endocrinol Metab |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Medknow Publications & Media Pvt Ltd
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5240071/ https://ncbi.nlm.nih.gov/pubmed/28217527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.194341 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|